EGFR and colorectal carcinoma: Matuzumab and panitumumab are two other monoclonal antibodies which can block EGFR activity; the antibodies are able to inhibit ligand-mediated activation followed by reduced EGFR signaling, cell cycle arrest, and reduced angiogenesis; clinical trials are in progress for CRC and NSCLC [8, 58, 59].